GlassScriptPhysician profile
Muhammad Azzouz
NPI 1417238270
$15,429.60
in general payments reported to CMS, 2019-2025
29 companies · $2,175 in 2025
The $2,175 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,463 · 2020: $1,615 · 2021: $899 · 2022: $2,723 · 2023: $2,674 · 2024: $880 · 2025: $2,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,474 · Travel and Lodging: $2,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,473.76 |
| Travel and Lodging | $2,255.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,933.51 | 2019-2025 | Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $3,594.00 | 2019-2025 | Triclip, Mitraclip, Amplatzer |
| Medtronic Vascular, INC. | $2,209.39 | 2019-2020 | |
| Boston Scientific Corporation | $2,123.19 | 2019-2024 | Watchman Access System |
| Abiomed | $1,279.29 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $431.83 | 2019-2024 | Lifevest |
| Medtronic, INC. | $300.94 | 2021-2024 | Corevalve Evolut R, Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $249.17 | 2019-2024 | Camzyos |
| Philips North America LLC | $180.35 | 2022-2025 | (Ck4) Mcot, Extended Holter |
| Chiesi USA, INC. | $117.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $117.00 | 2019-2024 | |
| Penumbra, INC. | $116.28 | 2025 | Indigo System |
| Janssen Pharmaceuticals, INC | $96.58 | 2019-2022 | |
| Cardiovascular Systems INC. | $84.41 | 2022-2023 | Diamondback Coronary |
| Shockwave Medical, INC | $82.08 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $78.63 | 2020-2025 | Nuvision Ice Catheter |
| Amgen INC. | $72.63 | 2020-2024 | Repatha |
| Biotronik INC. | $63.00 | 2019 | |
| Impulse Dynamics (USA) INC. | $55.69 | 2023 | Optimizer |
| W. L. Gore & Associates, INC. | $47.55 | 2025 | Gore Cardioform Asd Occluder |
| Astrazeneca Pharmaceuticals LP | $44.97 | 2020-2023 | Farxiga |
| Tactile Systems Technology INC | $39.55 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Terumo Medical Corporation | $23.59 | 2022 | |
| Cardiva Medical, INC. | $19.31 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Angiodynamics, INC. | $18.73 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $17.78 | 2019 | |
| Pfizer INC. | $15.06 | 2020 | |
| Lilly USA, LLC | $11.74 | 2019 | |
| Hitachi Healthcare Americas Corp. | $6.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Azzouz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.